Changes in Beneficial Ownership · 4
Scribe Therapeutics Inc.
SCTXNASDAQEQUITYCurrent
Changes in Beneficial Ownership
Structured filing — 4
form4-07292026_110744.xml
Filing details
- Report period
- 2026-07-27
- Issuer
- Scribe Therapeutics, Inc.
- Issuer CIK
- 0001853921
- Trading symbol
- SCTX
Reporting owner 1
- Name
- AH Bio Fund II, L.P.
- Reporting owner CIK
- 0001725721
- Relationship
- 10% owner
- Address
- C/O ANDREESSEN HOROWITZ, 2865 SAND HILL ROAD, SUITE 101, MENLO PARK, CA, 94025
Reporting owner 2
- Name
- AH Equity Partners Bio II, L.L.C.
- Reporting owner CIK
- 0001725722
- Relationship
- 10% owner
- Address
- C/O ANDREESSEN HOROWITZ, 2865 SAND HILL ROAD, SUITE 101, MENLO PARK, CA, 94025
Reporting owner 3
- Name
- AH Bio Fund III, L.P.
- Reporting owner CIK
- 0001799477
- Relationship
- 10% owner
- Address
- C/O ANDREESSEN HOROWITZ, 2865 SAND HILL ROAD, SUITE 101, MENLO PARK, CA, 94025
Reporting owner 4
- Name
- AH Equity Partners Bio III, L.L.C.
- Reporting owner CIK
- 0001799478
- Relationship
- 10% owner
- Address
- C/O ANDREESSEN HOROWITZ, 2865 SAND HILL ROAD, SUITE 101, MENLO PARK, CA, 94025
Reporting owner 5
- Name
- Andreessen Marc L
- Reporting owner CIK
- 0001160077
- Relationship
- 10% owner
- Address
- C/O ANDREESSEN HOROWITZ, 2865 SAND HILL ROAD, SUITE 101, MENLO PARK, CA, 94025
Reporting owner 6
- Name
- HOROWITZ BENJAMIN A
- Reporting owner CIK
- 0001166586
- Relationship
- 10% owner
- Address
- C/O ANDREESSEN HOROWITZ, 2865 SAND HILL ROAD, SUITE 101, MENLO PARK, CA, 94025
Non-derivative transactions
| Security | Transaction date | Code | Amount | A / D | Price (USD) | Owned after | Ownership | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | 2026-07-27 | C · Form 4 | 2,051,742 | A | [F1] | 2,051,742 | I | By AH Bio Fund II, L.P.[F2] |
| Common Stock | 2026-07-27 | C · Form 4 | 697,650 | A | [F1] | 697,650 | I | By AH Bio Fund III, L.P.[F3][F4] |
| Common Stock | 2026-07-27 | P · Form 4 | 333,333 | A | 15 | 2,385,075 | I | By AH Bio Fund II, L.P.[F2] |
Table key
- C · Form 4
- Derivative conversion
- A
- Acquired
- I
- Indirect
- P · Form 4
- Purchase on the market or privately
Derivative transactions
| Security | Conversion / exercise price (USD) | Transaction date | Code | Amount | A / D | Price (USD) | Exercisable | Expires | Underlying security | Underlying shares | Owned after | Ownership | Nature of ownership |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Series A Preferred Stock | [F1] | 2026-07-27 | C · Form 4 | 12,150,003 | D | 0 | [F1] | [F1] | Common Stock | 2,051,742 | 0 | I | By AH Bio Fund II, L.P.[F2] |
| Series B Preferred Stock | [F1] | 2026-07-27 | C · Form 4 | 4,131,344 | D | 0 | [F1] | [F1] | Common Stock | 697,650 | 0 | I | By AH Bio Fund III, L.P.[F3][F4] |
Table key
- C · Form 4
- Derivative conversion
- D
- Disposed
- I
- Indirect
Footnotes
- F1
- Series A Preferred Stock and Series B Preferred Stock converted into Common Stock immediately prior to the closing of the Issuer's initial public offering for no additional consideration, on a 5.9218-for-one basis, and had no expiration date.↩ 1↩ 2↩ 3↩ 4↩ 5↩ 6↩ 7↩ 8
- F2
- The reported securities are held by AH Bio Fund II, L.P. ("AH Bio Fund II"), for itself and as nominee for AH Bio Fund II-B, L.P. AH Equity Partners Bio II, L.L.C. ("AH EP Bio II") is the general partner of AH Bio Fund II and has sole voting and dispositive power with regard to the securities held by AH Bio Fund II for itself and as nominee. The managing members of AH EP Bio II are Marc Andreessen and Ben Horowitz. Marc Andreessen and Ben Horowitz may be deemed to share voting and dispositive power with respect to the securities held by AH Bio Fund II for itself and as nominee. Each of the Reporting Persons disclaims the existence of a "group" and disclaims beneficial ownership of the securities held by AH Bio Fund II for itself and as nominee (and this report shall not be deemed an admission that any such person is the beneficial owner of such securities), except to the extent of such person's pecuniary interest therein, if any.↩ 1↩ 2↩ 3
- F3
- The reported securities are held by AH Bio Fund III, L.P. ("AH Bio Fund III"), for itself and as nominee for AH Bio Fund III-B, L.P., AH Bio Fund III-Q, L.P. and CLF Partners II, LP. AH Equity Partners Bio III, L.L.C. ("AH EP Bio III") is the general partner of AH Bio Fund III and has sole voting and dispositive power with regard to the securities held by AH Bio Fund III for itself and as nominee. The managing members of AH EP Bio III are Marc Andreessen and Ben Horowitz. Marc Andreessen and Ben Horowitz may be deemed to share voting and dispositive power with respect to the securities held by AH Bio Fund III for itself and as nominee.↩ 1↩ 2
- F4
- (Continued from Footnote 3) Each of the Reporting Persons disclaims the existence of a "group" and disclaims beneficial ownership of the securities held by AH Bio Fund III for itself and as nominee (and this report shall not be deemed an admission that any such person is the beneficial owner of such securities), except to the extent of such person's pecuniary interest therein, if any.↩ 1↩ 2
Signature 1
- Signed
- AH Bio Fund II, L.P., By AH Equity Partners Bio II, L.L.C., Its General Partner, By /s/ Phil Hathaway, Chief Operating Officer
- Date
- 2026-07-29
Signature 2
- Signed
- AH Equity Partners Bio II, L.L.C., By /s/ Phil Hathaway, Chief Operating Officer
- Date
- 2026-07-29
Signature 3
- Signed
- AH Bio Fund III, L.P., By AH Equity Partners Bio III, L.L.C., Its General Partner, By /s/ Phil Hathaway, Chief Operating Officer
- Date
- 2026-07-29
Signature 4
- Signed
- AH Equity Partners Bio III, L.L.C., By /s/ Phil Hathaway, Chief Operating Officer
- Date
- 2026-07-29
Signature 5
- Signed
- /s/ Phil Hathaway, Attorney-in-Fact for Marc L. Andreessen
- Date
- 2026-07-29
Signature 6
- Signed
- /s/ Phil Hathaway, Attorney-in-Fact for Benjamin Horowitz
- Date
- 2026-07-29
Company context
We are a clinical-stage biotechnology company engineering purpose-built in vivo CRISPR technologies designed to extend healthy lifespan through disease prevention and durable therapeutic intervention. While current genetic medicines are largely limited to rare disorders, we are engineering our technologies for use in common diseases affecting millions. By targeting prevalent diseases with significant unmet need and high clinical burden, we aim to usher in a new era of broadly scalable, transformative, and preventative genetic medicines. Our focus is on cardiovascular and metabolic diseases with initial programs to address the key drivers of atherosclerotic cardiovascular disease, or ASCVD. We are designing CRISPR-based genetic medicines to be well-tolerated, effective, durable, and scalable enough to shift the treatment paradigm from symptom-driven intervention and chronic care to population-level prevention, with the goal of broadly democratizing access to the cardioprotective effects of known genetic variants. Our lead product candidate, STX-1150, utilizes ELXR, our highly engineered epigenetic silencing technology, and is designed to deliver persistent and potent LDL-C reductions without permanent genetic changes. STX-1150 is a demonstration of moving towards our goal to transform practical therapeutic adherence and real-world medical outcomes for patients in the multibillion-dollar LDL-C lowering landscape. We have secured regulatory clearance from the Australian Therapeu